OBJECTIVES: To assess [18 F]AV-1451 tau-PET (positron emission tomography) uptake patterns across the primary progressive aphasia (PPA) variants (logopenic, semantic, and agrammatic), examine regional uptake patterns of [18 F]AV-1451 independent of clinical diagnosis, and compare the diagnostic utility of [18 F]AV-1451, [18 F]-fluorodeoxygluclose (FDG)-PET and MRI (magnetic resonance imaging) to differentiate the PPA variants. METHODS: We performed statistical parametric mapping of [18 F]AV-1451 across 40 PPA patients (logopenic-PPA = 14, semantic-PPA = 13, and agrammatic-PPA = 13) compared to 80 cognitively normal, Pittsburgh compound B-negative controls, age and gender matched 2:1. Principal component analysis of regional [18 F]AV-1451 tau-PET standard uptake value ratio was performed to understand underlying patterns of [18 F]AV-1451 uptake independent of clinical diagnosis. Penalized multinomial regression analyses were utilized to assess diagnostic utility. RESULTS: Logopenic-PPA showed striking uptake throughout neocortex, particularly temporoparietal, compared to controls, semantic-PPA, and agrammatic-PPA. Semantic-PPA and agrammatic-PPA showed milder patterns of focal [18 F]AV-1451 uptake. Semantic-PPA showed elevated uptake (left>right) in anteromedial temporal lobes, compared to controls and agrammatic-PPA. Agrammatic-PPA showed elevated uptake (left>right) throughout prefrontal white matter and in subcortical gray matter structures, compared to controls and semantic-PPA. The principal component analysis of regional [18 F]AV-1451 indicated two primary dimensions, a severity dimension that distinguished logopenic-PPA from agrammatic-PPA and semantic-PPA, and a frontal versus temporal contrast that distinguishes agrammatic-PPA and semantic-PPA cases. Diagnostic utility of [18 F]AV-1451was superior to MRI and at least equal to FDG-PET. INTERPRETATION: [18 F]AV-1451binding characteristics differ across the PPA variants and were excellent at distinguishing between the variants. [18 F]AV-1451binding characteristics were as good or better than other brain imaging modalities utilized in clinical practice, suggesting that [18 F]AV-1451 may have clinical diagnostic utility in PPA. Ann Neurol 2018 Ann Neurol 2018;83:599-611.
OBJECTIVES: To assess [18 F]AV-1451 tau-PET (positron emission tomography) uptake patterns across the primary progressive aphasia (PPA) variants (logopenic, semantic, and agrammatic), examine regional uptake patterns of [18 F]AV-1451 independent of clinical diagnosis, and compare the diagnostic utility of [18 F]AV-1451, [18 F]-fluorodeoxygluclose (FDG)-PET and MRI (magnetic resonance imaging) to differentiate the PPA variants. METHODS: We performed statistical parametric mapping of [18 F]AV-1451 across 40 PPA patients (logopenic-PPA = 14, semantic-PPA = 13, and agrammatic-PPA = 13) compared to 80 cognitively normal, Pittsburgh compound B-negative controls, age and gender matched 2:1. Principal component analysis of regional [18 F]AV-1451 tau-PET standard uptake value ratio was performed to understand underlying patterns of [18 F]AV-1451 uptake independent of clinical diagnosis. Penalized multinomial regression analyses were utilized to assess diagnostic utility. RESULTS:Logopenic-PPA showed striking uptake throughout neocortex, particularly temporoparietal, compared to controls, semantic-PPA, and agrammatic-PPA. Semantic-PPA and agrammatic-PPA showed milder patterns of focal [18 F]AV-1451 uptake. Semantic-PPA showed elevated uptake (left>right) in anteromedial temporal lobes, compared to controls and agrammatic-PPA. Agrammatic-PPA showed elevated uptake (left>right) throughout prefrontal white matter and in subcortical gray matter structures, compared to controls and semantic-PPA. The principal component analysis of regional [18 F]AV-1451 indicated two primary dimensions, a severity dimension that distinguished logopenic-PPA from agrammatic-PPA and semantic-PPA, and a frontal versus temporal contrast that distinguishes agrammatic-PPA and semantic-PPA cases. Diagnostic utility of [18 F]AV-1451was superior to MRI and at least equal to FDG-PET. INTERPRETATION: [18 F]AV-1451binding characteristics differ across the PPA variants and were excellent at distinguishing between the variants. [18 F]AV-1451binding characteristics were as good or better than other brain imaging modalities utilized in clinical practice, suggesting that [18 F]AV-1451 may have clinical diagnostic utility in PPA. Ann Neurol 2018 Ann Neurol 2018;83:599-611.
Authors: Keith A Josephs; Dennis W Dickson; Melissa E Murray; Matthew L Senjem; Joseph E Parisi; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell Journal: Brain Lang Date: 2013-03-28 Impact factor: 2.381
Authors: Hugo Botha; Joseph R Duffy; Jennifer L Whitwell; Edythe A Strand; Mary M Machulda; Christopher G Schwarz; Robert I Reid; Anthony J Spychalla; Matthew L Senjem; David T Jones; Val Lowe; Clifford R Jack; Keith A Josephs Journal: Cortex Date: 2015-05-27 Impact factor: 4.027
Authors: V Deramecourt; F Lebert; B Debachy; M A Mackowiak-Cordoliani; S Bombois; O Kerdraon; L Buée; C-A Maurage; F Pasquier Journal: Neurology Date: 2009-11-25 Impact factor: 9.910
Authors: Kerstin Sander; Tammaryn Lashley; Priya Gami; Thibault Gendron; Mark F Lythgoe; Jonathan D Rohrer; Jonathan M Schott; Tamas Revesz; Nick C Fox; Erik Årstad Journal: Alzheimers Dement Date: 2016-02-15 Impact factor: 21.566
Authors: Keith A Josephs; John R Hodges; Julie S Snowden; Ian R Mackenzie; Manuela Neumann; David M Mann; Dennis W Dickson Journal: Acta Neuropathol Date: 2011-05-26 Impact factor: 17.088
Authors: John T O'Brien; James B Rowe; W R Bevan-Jones; Thomas E Cope; P Simon Jones; Luca Passamonti; Young T Hong; Tim D Fryer; Robert Arnold; Kieren S J Allinson; Jonathan P Coles; Franklin I Aigbirhio; Karalyn Patterson Journal: J Neurol Neurosurg Psychiatry Date: 2017-09-14 Impact factor: 10.154
Authors: Lucia A A Giannini; Sharon X Xie; Corey T McMillan; Mendy Liang; Andrew Williams; Charles Jester; Katya Rascovsky; David A Wolk; Sharon Ash; Edward B Lee; John Q Trojanowski; Murray Grossman; David J Irwin Journal: Ann Neurol Date: 2019-03-28 Impact factor: 10.422
Authors: Irene Sintini; Jonathan Graff-Radford; Matthew L Senjem; Christopher G Schwarz; Mary M Machulda; Peter R Martin; David T Jones; Bradley F Boeve; David S Knopman; Kejal Kantarci; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs; Jennifer L Whitwell Journal: Brain Date: 2020-07-01 Impact factor: 13.501
Authors: Rene L Utianski; Hugo Botha; Peter R Martin; Christopher G Schwarz; Joseph R Duffy; Heather M Clark; Mary M Machulda; Alissa M Butts; Val J Lowe; Clifford R Jack; Matthew L Senjem; Anthony J Spychalla; Jennifer L Whitwell; Keith A Josephs Journal: Brain Lang Date: 2019-08-13 Impact factor: 2.381
Authors: Rene L Utianski; Joseph R Duffy; Heather M Clark; Mary M Machulda; Dennis W Dickson; Jennifer L Whitwell; Keith A Josephs Journal: Cortex Date: 2019-02-21 Impact factor: 4.027
Authors: Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell Journal: Ann Neurol Date: 2020-09-12 Impact factor: 10.422
Authors: R L Utianski; J L Whitwell; C G Schwarz; J R Duffy; H Botha; H M Clark; M M Machulda; M L Senjem; D S Knopman; R C Petersen; C R Jack; V J Lowe; K A Josephs Journal: Eur J Neurol Date: 2018-07-26 Impact factor: 6.089